These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35084252)

  • 21. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
    Gonsalves WI; Buadi FK; Kumar SK
    Eur J Haematol; 2018 Feb; 100(2):215-217. PubMed ID: 29064593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
    Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation.
    Tang ASO; Ahmad Asnawi AW; Koh AZY; Chong SL; Liew PK; Selvaratnam V; Md Fauzi A; Lau NS; Tan SM
    Am J Case Rep; 2023 Mar; 24():e938868. PubMed ID: 36882990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
    Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
    Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
    Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
    JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Multiple myeloma with myelofibrosis at diagnosis and aggressive extramedullary relapse after autologous stem cell transplantation].
    Kodama Y; Saburi M; Kawano K; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
    Rinsho Ketsueki; 2024; 65(1):1-6. PubMed ID: 38311382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
    Gasparetto C; Bowles KM; Abdallah AO; Morris L; Mander G; Coppola S; Wang J; Ross JA; Bueno OF; Arriola E; Mateos MV
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):775-784. PubMed ID: 34551886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MUK
    Brown S; Sherratt D; Hinsley S; Flanagan L; Roberts S; Walker K; Hall A; Pratt G; Messiou C; Jenner M; Kaiser M;
    BMJ Open; 2021 Mar; 11(3):e046225. PubMed ID: 33762245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early relapse after complete remission of primary plasma cell leukaemia manifesting clonal evolution: A case report.
    Nyunt WWT; Abdul Jalil D; Zakariah NA; Abdul Karim N; Mohd Idris MR; Nasuruddin DN; Salwati SHUIB; Alauddin H; Tumian NR; Leong CF; Abdul Wahid SFS
    Malays J Pathol; 2020 Apr; 42(1):143-150. PubMed ID: 32342945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
    Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F; Vishwamitra D; Unger S; Macartney T; Pesko J; Yu Y; Salem AH; Ross JA; Hong WJ; Maciag PC; Pauff JM; Kumar S
    Am J Hematol; 2021 Apr; 96(4):418-427. PubMed ID: 33368455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
    Telek B; Méhes L; Batár P; Kiss A; Udvardy M
    Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy.
    Ueno T; Sugio Y; Ohta T; Uehara Y; Ohno Y
    Int J Hematol; 2021 Jun; 113(6):941-944. PubMed ID: 33483877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
    Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.